<DOC>
	<DOCNO>NCT02966691</DOCNO>
	<brief_summary>This clinical study design evaluate diagnostic performance VisioCyt test , would improve early diagnosis bladder cancer order optimize management individual patient part cancer diagnostic monitoring . The diagnostic method VisioCyt® device base analysis transmission fluorescence , urinary cytology slide prepare accord protocol VisioCyt .</brief_summary>
	<brief_title>Evaluation Diagnostic Performance VisioCyt® Test , Case Suspicion Urothelial Bladder Tumors</brief_title>
	<detailed_description>This clinical trial divide two main phase : I . The first one involve construction well image process algorithm learn sample . The learning sample include 600 virtual slide make urine sample first 600 patient enrol . II . The second one , evaluate evaluation sample , diagnostic performance test VisioCyt , identify patient versus without bladder tumor , use comparator result examination reference : histology . The evaluation sample include 400 slide , make urine sample last 400 patient enrol .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<criteria>Age ≥18 year Patient affiliate social security system Patient able understand protocol . Signature patient consent form start study Negative urine culture Patient program bladder Endoscopy : suspect bladder cancer ( de novo , monitor relapse ) Exploration low urinary tract exclude suspect bladder cancer prostate cancer Age &lt; 18 year Ongoing Urinary tract infection untreated Private person liberty guardianship ( include guardianship ) Bladder cancer exclude urothelial carcinoma Carcinoma high urinary tract , associate Lithiasis pathology Patient underwent renal transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>